NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Remdesivir for treating COVID-19 ID3808

Provisional Stakeholder list

Consultees	Commentators (no right to submit or appeal)
Company	<u>General</u>
Gilead Sciences (remdesivir)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Africa Advocacy Foundation	Board of Community Health Councils in
African Health Policy Network	Wales
Age UK	British National Formulary
Asthma Relief Charity	Care Quality Commission
Asthma UK	Chest, Heart and Stroke Scotland
Asthma UK and British Lung Foundation To a strict of the strict o	Department of Health, Social Services Department of Health, Social Services
Foundation	and Public Safety for Northern Ireland
Black Health Agency BEMDA: Black and Ethnic Minority	Healthcare Improvement Scotland
BEMDA: Black and Ethnic Minority Diabetes Association	Hospital Information Services - Jehovah's Witnesses
Bringing Us Together	Medicines and Healthcare products
British Heart Foundation	Regulatory Agency
British Lung Foundation	 National Association of Primary Care
Care and Support Alliance	National Pharmacy Association
Carers Federation	NHS Alliance
Carers Trust	NHS Confederation
Carers UK	Northern Ireland Chest, Heart and
Chinese National Healthy Living	Stroke Association
Centre	Scottish Medicines Consortium
Chinese Welfare Association	Welsh Health Specialised Services
Compassion in Dying	Committee
Cystic Fibrosis Trust	
Diabetes UK	Possible comparator companies
Equalities National Council	ADVANZ Pharma (dexamethasone)
Fifth Sense	Aspen (dexamethasone)
ICU Steps	Consilient health (dexamethasone)
Independent Age	Glenmark Pharmaceuticals
• JDRF	(dexamethasone)
Medical Information for Ethnic	Hameln Pharma (dexamethasone)
Minorities	Hospira UK (dexamethasone)
NARA – The Breathing Charity	Martindale Pharma (dexamethasone)
National BAME Transplant Alliance	Panpharma UK (dexamethasone)
Network of Sikh Organisations	

Consultees Commentators (no right to submit or appeal) Primary Immunodeficiency UK Rosemont Pharmaceuticals Race Equality Foundation (dexamethasone) Synchrony Pharma (dexamethasone) South Asian Health Foundation Thame Laboratories (dexamethasone) Specialised Healthcare Alliance Wockhardt UK (dexamethasone) Professional groups Association for Respiratory Relevant research groups Technology and Physiology Asthma, Allergy and Inflammation Association of Clinical Biochemists -Research Charity Microbiology Section **Breathing Matters** Association of Respiratory Nurse British Association for Lung Research **Specialists** Cochrane Acute Respiratory Infections British Association of Endocrine and Group **Thyroid Surgeons** Cochrane Airways Group **British Geriatrics Society** Cochrane Infectious Diseases Group **British Infection Association** Genomics England British Paediatric Respiratory Society Cochrane Metabolic & Endocrine **British Rhinological Society Disorders Group** British Society for Paediatric MRC Clinical Trials Unit **Endocrinology & Diabetes** National Institute for Health Research **British Thoracic Society** Associated Public Health groups ILD-IN: Interstitial Lung Diseases Interdisciplinary Network Public Health England Infection Prevention Society Public Health Wales National Metabolic Biochemistry Faculty of Public Health Medicine Network Royal Society for Public Health National Heart and Lung Institute **Primary Care Diabetes Society** Primary Care Respiratory Society UK Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology Society for General Microbiology **UK Clinical Pharmacy Association UK Clinical Virology Network UK Cystic Fibrosis Medical** Association **UK Primary Immunodeficiency** Network

Appendix C

Consultees	Commentators (no right to submit or appeal)
Others Department of Health and Social Care NHS England NHS Lancashire North CCG NHS Wandsworth CCG Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

Provisional stakeholder list for the technology appraisal of remdesivir for treating COVID-19 ID3808 Issue date: August 2020 © National Institute for Health and Care Excellence 2020. All rights reserved 3 of 4

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

All non-company commentators are invited to nominate clinical specialists or patient experts.		